<DOC>
	<DOC>NCT02565017</DOC>
	<brief_summary>The purpose of this study is to learn what cancer patients think about IBM Watson Oncology. IBM Watson Oncology is a computer program designed to help inform oncologists about the best chemotherapy choices for their patients. The investigators will conduct focus groups with cancer patients who have received chemotherapy treatment at MSK in order to understand cancer patients' thoughts about IBM Watson Oncology.</brief_summary>
	<brief_title>Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>MSKCC patient 18 years or older Breast, lung, or colorectal cancer MSK patient as per EMR or clinician judgment having either: Chemotherapeutic adjuvant or neoadjuvant treatment with the first chemo visit occurring within the past 8 months and primary treatment (i.e., surgery), occurring within the past 6 months)at MSK OR chemotherapeutic treatment for metastatic disease with the first chemo visit occurring within the past 8 months at MSK OR chemotherapeutic treatment through an ongoing MSK clinical trial as per clinician Residing in New York metroarea NonEnglish speakers because we do not have the resources to conduct and translate the focus groups into other languages Patients who are not or will not receive their cancer care at MSKCC. Patient unwilling or unable to provide informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>IBM Watson</keyword>
	<keyword>Clinical Decision Support System</keyword>
	<keyword>Patient Preferences</keyword>
	<keyword>15-226</keyword>
</DOC>